

An Innovative Community Based Model of Care among PWID in Napoli 2 Area

D'Antò M¹, Luiso V², Cuomo V and Ranucci RAN¹

¹UOC Internal Medicine, P.O."S.Maria delle Grazie", Pozzuoli (NA), Italy

²UOC Emergency Medicine, Az. Osp. Dei Colli, Napoli, Italy

Background and aims: The linkage to care of PWID still remains an important gap in HCV treatment in Southern Italy in particular during pandemic. We evaluated a new model of care to improve the LTC throughout a pathway simplification and decentralization of HCV care with a close collaboration with addiction centers and hospital specialist and use of remote monitoring.

Patients and methods: The project started from January 2019 and it is currently ongoing. Four addiction centers of Naples district were involved (Acerra, Pozzuoli, Giugliano, Casavatore). A complete hepatological assessment, including blood chemistry, ultrasound and transient elastography examination, was provided. Hospital specialist confirmed diagnosis and prescribed DAA by visit on site before pandemic and by remote engagement during pandemic.

Results: 500 patients were screened, 300 were positive and 200 were treated; 87% were active drugs users and 79% of them were receiving opioid substitution therapy; 30% presented genotype 1a, the 36% 1b and 28% 3a. Everyone was treated with DAAs regimens.

Discussion: The SVR was 99% and remote monitoring through phone and video calls was successful.

N. of pts	200
Age, mean ± SD	36
Male, n (%)	170 (85%)
Ways of drug administration, n (%)	
intravenous	174 (87%)
intranasal	16 (8%)
Any alcohol use, n (%)	10 (5%)
Current OST, n (%)	166 (83%)
Methadone, n (%)	124 (62%)
Suboxone, n (%)	34 (17%)
GHB, n (%)	8 (4%)
HCV Genotype, n (%)	
1a	60 (30%)
3a	56 (28%)
1b	72 (36%)
2	4 (2%)
4	8 (4%)
Stage of liver disease*, n (%)	
No or mild Fibrosis (F 0-1),	8 (40%)
Moderate or advanced fibrosis (F 2-3)	70 (35%)
Cirrhosis (F 4)	50 (25%)
Treatment, n (%)	
Sofosbuvir + Velpatasvir	90 (45%)
Glecaprevir + Pibrentasvir	76 (38%)
Gra+Elb	34 (17%)
Adherence to treatment, n (%)	
Drop-out	4 (2%)
Adherence <90%	194 (97%)
Reinfection	2 (1%)
SVR 12, n (%)	198 (99%)

OST: opioid substitution therapy; SVR 12: Sustained Virological Response at week 12
*evaluated with transient elastography: F0-1 (<7,1kPa), F2-3 (7,1–13 kPa), F4 (>13,1kPa)

Table 1 Characteristics of population.